

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

SYH2066 TABLETS OBTAIN CLINICAL TRIAL APPROVAL IN CHINA

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that SYH2066 Tablets (the “**Product**”) developed by the Group have obtained approval from the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China in September 2025.

The Product, a Class 1 innovative chemical drug independently developed by the Group, is a novel oral, small molecule candidate targeting respiratory syncytial virus (“**RSV**”). The approved indication is for the treatment of respiratory infections caused by RSV (the “**Disease**”). Preclinical studies demonstrated that the Product exhibited favorable pharmacokinetic properties, such as good oral bioavailability, and significantly reduced RSV viral titers in animal models of the Disease, with a high safety profile.

Currently, there are no approved small molecule drugs targeting RSV domestically or internationally. The Product is expected to become an effective therapeutic option for the Disease, providing a promising clinical development value.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 12 September 2025

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.